BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company focused on the development and development of antibody drugs. Today, the company operates innovative drug projects in thrombosis, cancer, atherosclerosis and eye diseases. In January 2007, the company announced a major agreement with American Genentech, Inc. in the cardiovascular area, and in June 2008, BioInvent, together with the partner ThromboGenics, signed a TB-403 agreement with Roche to commercialize the cancer project. The basis for these projects is a competitive and substantially patent-protected technology platform. The width and strength of this platform is also utilized by partners such as Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA.
BioInvent International AB
Address
Ideongatan 1A-D, 223 70 Lund
Building
Gamma 2
Company website
Phone
About Ideon
We are one of Sweden’s most renowned Science Parks and we have 40 years of history catalyzing innovation and supporting growing tech and deep tech companies. Our vision is to work with others to create the world’s best innovation ecosystem, with the aim of helping to change the world for the better. Collaboration is our most important core value and tool.